UT Health Science Center at Houston Trials

UT Health Science Center at Houston	Welcome, Profile Billing Logout

51 Trials

Active Trials

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Sevick, Eva M

NCT05129514: Imaging Lymphatic/Cerebrospinal Fluid (CSF) Drainage From the Head and Neck in Persons With Traumatic Brain Injury: Demonstration of Feasibility and Evaluation of Manual Therapy to Improve Drainage and Facilitate Cognitive Recovery

Not yet recruiting

N/A

Manual Lymphatic Drainage (MLD)

The University of Texas Health Science Center, Houston, HeadStrong Foundation

Trauma, Brain, Neuroinflammation

10/22

Winner, Paul K

TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting

800

Europe, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

05/24

05/25

APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting

285

Europe, Canada, US

Experimental: ALZ-801

Alzheon Inc.

Early Alzheimer's Disease

12/25

01/26

RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed

804

Canada, US, RoW

Simufilam, PTI-125, Placebo

Cassava Sciences, Inc., Premier Research Group plc

Alzheimer Disease

10/24

TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting

1200

Europe, Canada, Japan, US, RoW

Remternetug, LY3372993, Placebo

Eli Lilly and Company

Alzheimer's Disease

04/29

10/30

TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting

1667

Japan, US

Remternetug (IV), LY3372993, Remternetug (SC), Placebo

Eli Lilly and Company

Alzheimer's Disease

04/24

03/26

ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis

Active, not recruiting

1882

Europe, Canada, Japan, US, RoW

Ofatumumab, Tetanus toxoid (TT) containing vaccine (Td, Tdap), 13-valent pneumococcal conjugate vaccine (13-PCV), 23-valent pneumococcal polysaccharide vaccine (23-PPV), Seasonal Quadrivalent influenza vaccine, Keyhole limpet hemocyanin (KLH) neo-antigen

Novartis Pharmaceuticals

Relapsing Multiple Sclerosis

12/27

09/28

PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting

1633

Europe, Japan, US, RoW

Lasmiditan, LY573144, Placebo

Eli Lilly and Company

Migraine

11/26

PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting

1000

Europe, Japan, US, RoW

Lasmiditan, LY573144

Eli Lilly and Company

Migraine

01/28

LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Completed

2/3

554

ATH-1017, Placebo

Athira Pharma

Alzheimer Disease, Dementia of Alzheimer Type

07/24

NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Recruiting

300

Japan, US

Mevidalen, LY3154207, Placebo

Eli Lilly and Company

Alzheimer Disease

12/25

01/26

SIGNAL-AD, NCT04381468: SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

Completed

1/2

Pepinemab, Placebo

Vaccinex Inc., Alzheimer's Drug Discovery Foundation, Alzheimer's Association

Alzheimer Disease

06/24

Cho, Raymond

NCT04541329: Predicting Inflammatory Skin Disease Response to IL-23 Blockade

Completed

Tildrakizumab

University of California, San Francisco, Sun Pharmaceutical Industries Limited

Psoriasis Vulgaris

01/23

NCT05390515: Psoriatic Immune Response to Tildrakizumab

Recruiting

Tildrakizumab Prefilled Syringe

University of California, San Francisco, Sun Pharmaceutical Industries Limited

Psoriasis Vulgaris

09/25

NCT05858619: Molecular Signatures of Cutaneous Dupilumab Response

Recruiting

Dupilumab

University of California, San Francisco

Atopic Dermatitis

02/26

NCT05858645: Correction of Psoriatic T Cell Signatures by Deucravacitinib

Recruiting

deucravacitinib

University of California, San Francisco, Bristol-Myers Squibb

Psoriasis Vulgaris

06/26

NCT05858632: Immune Spatial Features of Guselkumab Cutaneous Response

Recruiting

Guselkumab

University of California, San Francisco, Janssen Scientific Affairs, LLC

Psoriasis of Scalp

06/26

MBD, NCT03395392: NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

Completed

2/3

NRX-101, Lurasidone HCl, Latuda

NeuroRx, Inc., Prevail Infoworks, Inc

Bipolar Depression, Suicidal Ideation and Behavior

02/24

03/24

ABOVE, NCT03459456: Measuring Automated Behavioral Observations & Vocal Expressions

Active, not recruiting

N/A

Provocation OC task (Provoc), Trier Social Stress Test (TSST), Exposure provocation task

Baylor College of Medicine, Brown University, University of Pittsburgh

OCD, Obsessive-Compulsive Disorder

07/25

LIFU, NCT05467085: Imaging-Guided Low Intensity Focused Ultrasound

Active, not recruiting

N/A

BX Pulsar 1002, Low Intensity Focused Ultrasound Pulsation (LIFUP)

Baylor College of Medicine, Massachusetts General Hospital, M.D. Anderson Cancer Center

Obsessive-Compulsive Disorder

08/25

NCT03313622: Locating Biomarkers in OCD Through Behavioral Tasks

Not yet recruiting

N/A

Beads Task, PROVOC Tasks

Baylor College of Medicine, Brown University, University of Pittsburgh, Butler Hospital

OCD, Obsessive-Compulsive Disorder

03/26

Fenoy, Albert J

NCT06096207: DBS for Depression

Recruiting

Medtronic SenSight Directional DBS lead

Northwell Health, Medtronic

Treatment Resistant Depression

10/30

10/38

NCT04758624: Elucidating the Temporality of Structural and Functional Connectivity Changes in Essential Tremor After Successful Deep Brain Stimulation to the Dentato-rubro-thalamic Tract

Recruiting

N/A

Deep Brain Stimulation

Northwell Health, National Institutes of Health (NIH)

Essential Tremor

08/26

NCT02773082: DBS for Obsessive-Compulsive Disorder

Recruiting

N/A

Reclaim™ DBS Therapy

Northwell Health, Medtronic

Obsessive-Compulsive Disorder (OCD)

01/30

Schulz, Paul

TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting

800

Europe, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

05/24

05/25

APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting

285

Europe, Canada, US

Experimental: ALZ-801

Alzheon Inc.

Early Alzheimer's Disease

12/25

01/26

TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting

1200

Europe, Canada, Japan, US, RoW

Remternetug, LY3372993, Placebo

Eli Lilly and Company

Alzheimer's Disease

04/29

10/30

TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting

1667

Japan, US

Remternetug (IV), LY3372993, Remternetug (SC), Placebo

Eli Lilly and Company

Alzheimer's Disease

04/24

03/26

NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

2196

Japan, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer Disease

11/27

NCT04513158: Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

Terminated

Convalescent Plasma

Joseph M. Flynn, D.O., MPH

Covid19

04/21

NCT06775964: Stem Cell Therapy for Early Alzheimer's Disease

Not yet recruiting

1/2

adMSC

Paul E Schulz, Weston Brain Institute

Cognitive Dysfunction

12/26

01/27

NCT05880849: Choline Effects - Pre-symptomatic AD

Recruiting

Choline, Choline Bitartrate, VitaCholine(R)

Paul E Schulz, M.D. Anderson Cancer Center, Massachusetts Institute of Technology, Balchem Corporation

Alzheimer Disease

09/25

09/26

Farrell, Christine

NCT05880849: Choline Effects - Pre-symptomatic AD

Recruiting

Choline, Choline Bitartrate, VitaCholine(R)

Paul E Schulz, M.D. Anderson Cancer Center, Massachusetts Institute of Technology, Balchem Corporation

Alzheimer Disease

09/25

09/26

Rivera, Angielyn

LEAP, NCT05176626: Long-term Effectiveness of the Antiobesity Medication Phentermine

Active, not recruiting

870

Online Lifestyle Behavioral Therapy, Phentermine Hydrochloride 8 MG, Lomaira

Wake Forest University Health Sciences, Johns Hopkins University, Kaiser Permanente, HealthPartners Institute, The University of Texas Health Science Center, Houston, Biomedical Research Institute of New Mexico, WW International Inc, KVK-Tech, Inc., National Heart, Lung, and Blood Institute (NHLBI)

Obesity, Obesity; Drug, Lifestyle, Healthy

12/26

NCT05492721: Comparing Tissue Adhesives in Port Site Closure

Recruiting

184

2-Octylcyanoacrylate, Dermabond, N-butyl-2-cyanoacrylate, Swiftset

The University of Texas Health Science Center, Houston

Dermatitis, Contact

06/25

10/25

NCT05046730: SEAM Trial: Sutureless End to End Anastomosis by Magnetic Compression

Terminated

N/A

128

Ileostomy Reversal using Self Forming Magnets (SFM)

GI Windows, Inc.

Retraction of Ileostomy

10/23

12/23

NCT05775133: Feasibility and Utility of Artificial Intelligence (AI) / Machine Learning (ML) - Driven Advanced Intraoperative Visualization and Identification of Critical Anatomic Structures and Procedural Phases in Laparoscopic Cholecystectomy

Recruiting

N/A

120

ICG

Activ Surgical

Cholecystitis, Cholelithiasis, Biliary Dyskinesia

12/25

NCT05838300: Lexion AP 50/30 Warmed Humidified Real Time CO2 Insufflation Vs Airseal Recirculated CO2/Air Insufflation in Minimally Invasive Bariatric (Gastric Bypass) Surgery

Recruiting

N/A

Warm humidified CO2, Dry CO2

The University of Texas Health Science Center, Houston

Bariatric Surgery

06/25

AUDACITY, NCT05368259: The Study (AllUrion Device in Adults With Clinical ObesITY)

Active, not recruiting

N/A

1000

AGBS, Allurion Gastric Balloon System (AGBS)

Allurion Technologies

Obesity

11/24

03/25

Rasmussen, John

NCT05937269: Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship

Enrolling by invitation

Near-infrared fluorescence lymphatic imaging, indocyanine green imaging, advanced pneumatic compression therapy

The University of Texas Health Science Center, Houston

Lymphedema of Face, Head and Neck Cancer

02/25

Watson, David

TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting

800

Europe, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

05/24

05/25

APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting

285

Europe, Canada, US

Experimental: ALZ-801

Alzheon Inc.

Early Alzheimer's Disease

12/25

01/26

TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting

1200

Europe, Canada, Japan, US, RoW

Remternetug, LY3372993, Placebo

Eli Lilly and Company

Alzheimer's Disease

04/29

10/30

REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated

1125

Canada, US, RoW

Simufilam, PTI-125, Placebo

Cassava Sciences, Inc., Premier Research Group plc

Alzheimer Disease

12/24

TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting

1667

Japan, US

Remternetug (IV), LY3372993, Remternetug (SC), Placebo

Eli Lilly and Company

Alzheimer's Disease

04/24

03/26

NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Active, not recruiting

2/3

225

Canada, US

Piromelatine 20 mg, Neu-P11, Placebo

Neurim Pharmaceuticals Ltd., Syneos Health

Alzheimer's Disease

06/25

NCT06677203: Study of ASN51 in Adults With Early Alzheimer's Disease

Terminated

123

ASN51, Placebo

Asceneuron S.A.

Alzheimer Disease

11/24

NCT06750432: PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

Recruiting

128

PMN310, Placebo

ProMis Neurosciences, Inc

Alzheimer Disease, Early Onset

07/26

12/26

LEARN, NCT05757908: Study Comparing At-Home Mobile Spirometry to In-Clinic in Moderate Asthma Participants Taking Long-Acting Beta Agonist

Completed

N/A

Long-Acting Beta Agonist, LABA

Koneksa Health

Moderate Asthma

11/23

MAGMAP, NCT05899985: Magnetic Sentinel Lymph Node Mapping in Upper Gastro-Intestinal Cancer: A Feasibility Clinical Investigation

Recruiting

N/A

RoW

FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System

Ferronova Pty Ltd, Royal Adelaide Hospital, Austin Health, Flinders Medical Centre, Peter MacCallum Cancer Centre, Australia, South Australian Health and Medical Research Institute

Gastric Cancer, Esophageal Cancer

02/25

02/30

D-Psy adultes, NCT05675215: External Validation by Machine Learning and Reduction of the Input Dimensions of the D-PSY Scale for Dimensional Psychopathology

Recruiting

N/A

200

Europe

Psychopathology screening tests

Institut pour la Pratique et l'Innovation en PSYchologie appliquÃ©e (Institut Pi-Psy), BPIfrance

Psychopathology

03/23

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Sevick, Eva M

Not yet recruiting

N/A

Manual Lymphatic Drainage (MLD)

The University of Texas Health Science Center, Houston, HeadStrong Foundation

Trauma, Brain, Neuroinflammation

10/22

Winner, Paul K

TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting

800

Europe, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

05/24

05/25

APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting

285

Europe, Canada, US

Experimental: ALZ-801

Alzheon Inc.

Early Alzheimer's Disease

12/25

01/26

RETHINK-1, NCT04994483: Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease

Completed

804

Canada, US, RoW

Simufilam, PTI-125, Placebo

Cassava Sciences, Inc., Premier Research Group plc

Alzheimer Disease

10/24

TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting

1200

Europe, Canada, Japan, US, RoW

Remternetug, LY3372993, Placebo

Eli Lilly and Company

Alzheimer's Disease

04/29

10/30

TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting

1667

Japan, US

Remternetug (IV), LY3372993, Remternetug (SC), Placebo

Eli Lilly and Company

Alzheimer's Disease

04/24

03/26

ALITHIOS, NCT03650114 / 2017-004703-51: Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Jan 2028 - Dec 2028: Data from ALITHIOS trial for multiple sclerosis

Active, not recruiting

1882

Europe, Canada, Japan, US, RoW

Novartis Pharmaceuticals

Relapsing Multiple Sclerosis

12/27

09/28

PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting

1633

Europe, Japan, US, RoW

Lasmiditan, LY573144, Placebo

Eli Lilly and Company

Migraine

11/26

PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting

1000

Europe, Japan, US, RoW

Lasmiditan, LY573144

Eli Lilly and Company

Migraine

01/28

LIFT-AD, NCT04488419: ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease

Completed

2/3

554

ATH-1017, Placebo

Athira Pharma

Alzheimer Disease, Dementia of Alzheimer Type

07/24

NCT06538116: A Study of Mevidalen (LY3154207) in Participants With Alzheimer's Disease

Recruiting

300

Japan, US

Mevidalen, LY3154207, Placebo

Eli Lilly and Company

Alzheimer Disease

12/25

01/26

SIGNAL-AD, NCT04381468: SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

Completed

1/2

Pepinemab, Placebo

Vaccinex Inc., Alzheimer's Drug Discovery Foundation, Alzheimer's Association

Alzheimer Disease

06/24

Cho, Raymond

NCT04541329: Predicting Inflammatory Skin Disease Response to IL-23 Blockade

Completed

Tildrakizumab

University of California, San Francisco, Sun Pharmaceutical Industries Limited

Psoriasis Vulgaris

01/23

NCT05390515: Psoriatic Immune Response to Tildrakizumab

Recruiting

Tildrakizumab Prefilled Syringe

University of California, San Francisco, Sun Pharmaceutical Industries Limited

Psoriasis Vulgaris

09/25

NCT05858619: Molecular Signatures of Cutaneous Dupilumab Response

Recruiting

Dupilumab

University of California, San Francisco

Atopic Dermatitis

02/26

NCT05858645: Correction of Psoriatic T Cell Signatures by Deucravacitinib

Recruiting

deucravacitinib

University of California, San Francisco, Bristol-Myers Squibb

Psoriasis Vulgaris

06/26

NCT05858632: Immune Spatial Features of Guselkumab Cutaneous Response

Recruiting

Guselkumab

University of California, San Francisco, Janssen Scientific Affairs, LLC

Psoriasis of Scalp

06/26

MBD, NCT03395392: NRX-101 for Bipolar Depression With Subacute Suicidal Ideation

Completed

2/3

NRX-101, Lurasidone HCl, Latuda

NeuroRx, Inc., Prevail Infoworks, Inc

Bipolar Depression, Suicidal Ideation and Behavior

02/24

03/24

ABOVE, NCT03459456: Measuring Automated Behavioral Observations & Vocal Expressions

Active, not recruiting

N/A

Provocation OC task (Provoc), Trier Social Stress Test (TSST), Exposure provocation task

Baylor College of Medicine, Brown University, University of Pittsburgh

OCD, Obsessive-Compulsive Disorder

07/25

LIFU, NCT05467085: Imaging-Guided Low Intensity Focused Ultrasound

Active, not recruiting

N/A

BX Pulsar 1002, Low Intensity Focused Ultrasound Pulsation (LIFUP)

Baylor College of Medicine, Massachusetts General Hospital, M.D. Anderson Cancer Center

Obsessive-Compulsive Disorder

08/25

NCT03313622: Locating Biomarkers in OCD Through Behavioral Tasks

Not yet recruiting

N/A

Beads Task, PROVOC Tasks

Baylor College of Medicine, Brown University, University of Pittsburgh, Butler Hospital

OCD, Obsessive-Compulsive Disorder

03/26

Fenoy, Albert J

NCT06096207: DBS for Depression

Recruiting

Medtronic SenSight Directional DBS lead

Northwell Health, Medtronic

Treatment Resistant Depression

10/30

10/38

NCT04758624: Elucidating the Temporality of Structural and Functional Connectivity Changes in Essential Tremor After Successful Deep Brain Stimulation to the Dentato-rubro-thalamic Tract

Recruiting

N/A

Deep Brain Stimulation

Northwell Health, National Institutes of Health (NIH)

Essential Tremor

08/26

NCT02773082: DBS for Obsessive-Compulsive Disorder

Recruiting

N/A

Reclaim™ DBS Therapy

Northwell Health, Medtronic

Obsessive-Compulsive Disorder (OCD)

01/30

Schulz, Paul

TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting

800

Europe, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

05/24

05/25

APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting

285

Europe, Canada, US

Experimental: ALZ-801

Alzheon Inc.

Early Alzheimer's Disease

12/25

01/26

TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting

1200

Europe, Canada, Japan, US, RoW

Remternetug, LY3372993, Placebo

Eli Lilly and Company

Alzheimer's Disease

04/29

10/30

TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting

1667

Japan, US

Remternetug (IV), LY3372993, Remternetug (SC), Placebo

Eli Lilly and Company

Alzheimer's Disease

04/24

03/26

NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

2196

Japan, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer Disease

11/27

NCT04513158: Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection

Terminated

Convalescent Plasma

Joseph M. Flynn, D.O., MPH

Covid19

04/21

NCT06775964: Stem Cell Therapy for Early Alzheimer's Disease

Not yet recruiting

1/2

adMSC

Paul E Schulz, Weston Brain Institute

Cognitive Dysfunction

12/26

01/27

NCT05880849: Choline Effects - Pre-symptomatic AD

Recruiting

Choline, Choline Bitartrate, VitaCholine(R)

Paul E Schulz, M.D. Anderson Cancer Center, Massachusetts Institute of Technology, Balchem Corporation

Alzheimer Disease

09/25

09/26

Farrell, Christine

NCT05880849: Choline Effects - Pre-symptomatic AD

Recruiting

Choline, Choline Bitartrate, VitaCholine(R)

Paul E Schulz, M.D. Anderson Cancer Center, Massachusetts Institute of Technology, Balchem Corporation

Alzheimer Disease

09/25

09/26

Rivera, Angielyn

LEAP, NCT05176626: Long-term Effectiveness of the Antiobesity Medication Phentermine

Active, not recruiting

870

Online Lifestyle Behavioral Therapy, Phentermine Hydrochloride 8 MG, Lomaira

Obesity, Obesity; Drug, Lifestyle, Healthy

12/26

NCT05492721: Comparing Tissue Adhesives in Port Site Closure

Recruiting

184

2-Octylcyanoacrylate, Dermabond, N-butyl-2-cyanoacrylate, Swiftset

The University of Texas Health Science Center, Houston

Dermatitis, Contact

06/25

10/25

NCT05046730: SEAM Trial: Sutureless End to End Anastomosis by Magnetic Compression

Terminated

N/A

128

Ileostomy Reversal using Self Forming Magnets (SFM)

GI Windows, Inc.

Retraction of Ileostomy

10/23

12/23

Recruiting

N/A

120

ICG

Activ Surgical

Cholecystitis, Cholelithiasis, Biliary Dyskinesia

12/25

NCT05838300: Lexion AP 50/30 Warmed Humidified Real Time CO2 Insufflation Vs Airseal Recirculated CO2/Air Insufflation in Minimally Invasive Bariatric (Gastric Bypass) Surgery

Recruiting

N/A

Warm humidified CO2, Dry CO2

The University of Texas Health Science Center, Houston

Bariatric Surgery

06/25

AUDACITY, NCT05368259: The Study (AllUrion Device in Adults With Clinical ObesITY)

Active, not recruiting

N/A

1000

AGBS, Allurion Gastric Balloon System (AGBS)

Allurion Technologies

Obesity

11/24

03/25

Rasmussen, John

NCT05937269: Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship

Enrolling by invitation

Near-infrared fluorescence lymphatic imaging, indocyanine green imaging, advanced pneumatic compression therapy

The University of Texas Health Science Center, Houston

Lymphedema of Face, Head and Neck Cancer

02/25

Watson, David

TRAILBLAZER-ALZ 6, NCT05738486: A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease

Active, not recruiting

800

Europe, US

Donanemab, LY3002813, Placebo

Eli Lilly and Company

Alzheimer's Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders

05/24

05/25

APOLLOE4-LTE, NCT06304883: Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

Active, not recruiting

285

Europe, Canada, US

Experimental: ALZ-801

Alzheon Inc.

Early Alzheimer's Disease

12/25

01/26

TRAILRUNNER-ALZ 3, NCT06653153: A Study of Remternetug (LY3372993) in Early Alzheimer's Disease

Recruiting

1200

Europe, Canada, Japan, US, RoW

Remternetug, LY3372993, Placebo

Eli Lilly and Company

Alzheimer's Disease

04/29

10/30

REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated

1125

Canada, US, RoW

Simufilam, PTI-125, Placebo

Cassava Sciences, Inc., Premier Research Group plc

Alzheimer Disease

12/24

TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease

Active, not recruiting

1667

Japan, US

Remternetug (IV), LY3372993, Remternetug (SC), Placebo

Eli Lilly and Company

Alzheimer's Disease

04/24

03/26

NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Active, not recruiting

2/3

225

Canada, US

Piromelatine 20 mg, Neu-P11, Placebo

Neurim Pharmaceuticals Ltd., Syneos Health

Alzheimer's Disease

06/25

NCT06677203: Study of ASN51 in Adults With Early Alzheimer's Disease

Terminated

123

ASN51, Placebo

Asceneuron S.A.

Alzheimer Disease

11/24

NCT06750432: PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)

Recruiting

128

PMN310, Placebo

ProMis Neurosciences, Inc

Alzheimer Disease, Early Onset

07/26

12/26

LEARN, NCT05757908: Study Comparing At-Home Mobile Spirometry to In-Clinic in Moderate Asthma Participants Taking Long-Acting Beta Agonist

Completed

N/A

Long-Acting Beta Agonist, LABA

Koneksa Health

Moderate Asthma

11/23

MAGMAP, NCT05899985: Magnetic Sentinel Lymph Node Mapping in Upper Gastro-Intestinal Cancer: A Feasibility Clinical Investigation

Recruiting

N/A

RoW

FerroTrace® and FerroMag Sentinel Lymph Node Mapping (SLNM) System

Ferronova Pty Ltd, Royal Adelaide Hospital, Austin Health, Flinders Medical Centre, Peter MacCallum Cancer Centre, Australia, South Australian Health and Medical Research Institute

Gastric Cancer, Esophageal Cancer

02/25

02/30

D-Psy adultes, NCT05675215: External Validation by Machine Learning and Reduction of the Input Dimensions of the D-PSY Scale for Dimensional Psychopathology

Recruiting

N/A

200

Europe

Psychopathology screening tests

Psychopathology

03/23

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites